Rafat Ansari

7.2k citations

109 papers · 5.3k indexed · 2 hit papers · h-index 34

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in

Oncology 88
- Lung Cancer Research Studies 53
- Cancer Treatment and Pharmacology 22
- Colorectal Cancer Treatments and Studies 21
Pulmonary and Respiratory Medicine 71
- Lung Cancer Treatments and Mutations 55
- Lung Cancer Diagnosis and Treatment 23
- Gastric Cancer Management and Outcomes 9

Co-authors: Nasser H. Hanna Lawrence H. Einhorn William B. Fisher Patrick J. Loehrer Ramaswamy Govindan Alan Sandler A. Wong Paulo M. Hoff
Journals: Journal of Clinical Oncology (45 papers)Annals of Oncology (13 papers)Journal of Thoracic Oncology (12 papers)Lung Cancer (9 papers)Investigational New Drugs (7 papers)
Partner nations: United States Australia Germany

In The Last Decade

Rafat Ansari

108 papers receiving 5.2k citations

Hit Papers

align trajectories log scale

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer 2006 · 500 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2006 Journal of Clinical Oncology
2001 Journal of Clinical Oncology

Peers

Countries citing papers authored by Rafat Ansari

Since Specialization

Citations

This map shows the geographic impact of Rafat Ansari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafat Ansari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafat Ansari more than expected).

Fields of papers citing papers by Rafat Ansari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafat Ansari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafat Ansari. The network helps show where Rafat Ansari may publish in the future.

Co-authors

The 25 scholars most cited alongside Rafat Ansari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rafat Ansari Line = papers co-authored together Rafat Ansari links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT Annals of Oncology ·Howard S. Höchster, Axel Grothey, L. Hart, Kendrith M. Rowland, Rafat Ansari, Steven R. Alberts, N. M. Chowhan, R. K. Ramanathan, Mark Keaton, John D. Hainsworth, Barrett H. Childs	2014	47
2	A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528 Journal of Thoracic Oncology ·Grace K. Dy, Sumithra J. Mandrekar, Garth D. Nelson, Jeffrey P. Meyers, Araba A. Adjei, (unknown), Helen J. Ross, Rafat Ansari, Alan P. Lyss, Philip J. Stella, Steven E. Schild, Julian R. Molina, Alex A. Adjei	2012	36
3	Sunitinib Plus Paclitaxel in Patients with Advanced Esophageal Cancer: A Phase II Study from the Hoosier Oncology Groupe Journal of Thoracic Oncology ·Zu Yin Pu, Yuchun Tang, William B. Fisher, Rafat Ansari, Erwin Robin, Geralda Aparecida do Carmo Schyra, J. McClean, Ziyue Liu, Yan Tong, Nasser H. Hanna	2012	22
4	Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206 Journal of Thoracic Oncology ·Michael J. Kelley, Jeffrey A. Bogart, Anindita Mahitala, Rafat Ansari, James N. Atkins, Herbert Pang, Mark R. Green, Everett E. Vokes	2012	21
5	Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology Annals of Oncology ·Shadia I. Jalal, 洋三中村, A. Melnyk, Donald Richards, A.M. Prokhorov, M. Neubauer, Rafat Ansari, Ramaswamy Govindan, Daniel Bruetman, William B. Fisher, T. Breen, Cynthia S. Johnson, Menggang Yu, Lawrence H. Einhorn, Nasser H. Hanna	2011	58
6	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial The Lancet ·Roy S. Herbst, Rafat Ansari, F. Bustin, Patrick J. Flynn, Lowell L. Hart, Gregory A. Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula G. O’Connor, John D. Hainsworth	2011	316
7	Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat Ansari, Michael Thomas, Mansoor N. Saleh, Robert McCroskey, Wolfgang Pfeifer, Thomas Marsland, Goetz Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, Richard I. Markowitz, Mark A. Socinski	2010	45
8	A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Coleman K. Obasaju, Rafat Ansari, Mark A. Socinski, Ruqin Chen, Matthew Monberg, Robert B. Catalano, Donna M. Marinucci, Darla Liles, Reimund Bliihm, Robert L. Comis, Joseph Treat	2010	7
9	Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group Journal of Thoracic Oncology ·Shadia I. Jalal, David Waterhouse, Martin J. Edelman, Sreenivasa Nattam, Rafat Ansari, Geralda Aparecida do Carmo Schyra, J. A. Balmer, Mark Richards, Jingwei Wu, Menggang Yu, А А Зобнин, Angela White, Nasser H. Hanna	2009	12
10	Survival analysis of colorectal cancer in patients underwent surgical operation in Shariati and Mehr Hospital-Tehran, in a retrospective study. Rafat Ansari, Hiva Amjadi, K. B. N., Tariq Almudhaiyan, Mayra Lisseth López, Nurlan Nurlybayev, Reza Malekzadeh	2007	10
11	Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus Annals of Oncology ·Ann M. Mauer, Eric H. Kraut, S Krauß, Rafat Ansari, Kristen Kasza, Livia L. Szeto, Everett E. Vokes	2005	48
12	Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer Annals of Oncology ·Chandra P. Belani, J. S. Lee, Mark A. Socinski, Francisco Robert, David Waterhouse, Kendrith M. Rowland, Rafat Ansari, Rogério Lilenbaum, Ronald B. Natale	2005	106
13	Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung cancer Annals of Oncology ·Ann M. Mauer, Rafat Ansari, P C Hoffman, S Krauß, David Taber, Mount Pm, S. Albergo, Thomas G. Cotter, L. Philip Schumm, Livia L. Szeto, Everett E. Vokes	2003	3
14	A phase III randomized study of carboplatin and paclitaxel with or without amifostine in patients with non-small cell lung cancer (NSCLC) Lung Cancer ·Chandra P. Belani, Rafat Ansari, JN Atkins, Jeremy K. Hon, Manuel Modiano, Thomas Budd	2000	1
15	Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung Cancer American Journal of Clinical Oncology ·Guru Sonpavde, Rafat Ansari, Paul Walker, Monique E. DePaepe, S. Albergo, Виталий Вячеславович Наумкин, René Gonin, Lawrence H. Einhorn	2000	27
16	Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer Investigational New Drugs ·Sridhar Mani, John W. Kugler, James A. Knost, Monique E. DePaepe, Joseph Gibbons, Juan Carlos García‐Ruiz, Rafat Ansari, Richard L. Schilsky, Everett E. Vokes	1998	27
17	Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer. Journal of Clinical Oncology ·Gini F. Fleming, J. W. Kugler, P C Hoffman, Rafat Ansari, Bitran Jd, Erin Thompson, K. Freitag, Adedigbo A. Fasanmade, Mark J. Ratain, Everett E. Vokes	1998	16
18	Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer Investigational New Drugs ·Scott Saxman, Patrick J. Loehrer, Aldi Tupalessy, 赟陈, R L Whitely, Daniel C. Scullin, Lawrence H. Einhorn, Rafat Ansari	1991	20
19	Etoposide and Split-Dose Cisplatin in Bronchogenic Carcinoma American Journal of Clinical Oncology ·Richard C. Lauer, William B. Fisher, Kenneth Pennington, Rafat Ansari, Lawrence H. Einhorn, Patrick J. Loehrer	1988	3
20	A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. Journal of Clinical Oncology ·Patrick J. Loehrer, Khaled Rahoui, Paul Kubilis, B.P. Vasil'ev, Andrew V. Ruoss, Rafat Ansari, Deborah M. Stephens, Solange Gomes Leonel, 红红	1988	61

About Rafat Ansari

Rafat Ansari is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Hepatology, Molecular Biology and Epidemiology, having authored 109 papers that have together received 5.3k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (55 papers), Lung Cancer Research Studies (53 papers), Cancer therapeutics and mechanisms (26 papers), Lung Cancer Diagnosis and Treatment (23 papers), Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (21 papers), Neuroendocrine Tumor Research Advances (15 papers) and Gastric Cancer Management and Outcomes (9 papers). The work is most often cited by research in Oncology (3.9k citations), Pulmonary and Respiratory Medicine (2.7k citations), Geriatrics and Gerontology (164 citations), Hepatology (313 citations) and Epidemiology (972 citations). Rafat Ansari has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Nasser H. Hanna, Lawrence H. Einhorn, William B. Fisher, Patrick J. Loehrer, Ramaswamy Govindan, Alan Sandler, A. Wong, Paulo M. Hoff, Mario Kuperminc and Hans Ulrich Burger. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact